FDA Approves AstraZeneca's Imfinzi for Muscle-Invasive Bladder Cancer

The FDA approved AstraZeneca’s Imfinzi (durvalumab) with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi alone after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval adds a treatment option for this patient group; the article reports no financial figures or stock-price impact.